VC and Investment
Biotechnology
UK pharma major AstraZeneca has agreed to invest $2 billion in US biotech company Summit Therapeutics, alongside a clinical partnership to test cancer drug combinations involving Summit’s bispecific antibody ivonescimab. 29 September 2026
Today's issue
Refine search
Biotechnology
Life science investor Syncona announces that it has committed $10.1 million (£7.5 million) to a $310 million (£230 million) Series C financing of its portfolio company OMass Therapeutics, a UK based biotechnology company developing small molecule therapeutics against highly validated targets. 15 October 2026
Biotechnology
US biotech company Verastem Oncology has priced a $250 million offering alongside new results for its experimental cancer drug VS-7375, as it prepares to expand development into three Phase III trials. 15 October 2026
Biotechnology
Boston, USA-based RNA therapies company Soufflé Therapeutics has closed an oversubscribed $135 million Series B financing led by Juvia Group, to fund first clinical studies in facioscapulohumeral muscular dystrophy (FSHD), heart failure and muscle and metabolic disorders. 14 October 2026
Biotechnology
US biotech companies Bambusa Therapeutics and Aspen Neuroscience have filed for initial public offerings (IPOs), seeking funding as they prepare further trials of bispecific antibodies and a patient-derived cell therapy for Parkinson’s disease, respectively. 13 October 2026
Biotechnology
US biotech City Therapeutics is seeking about $175 million in an initial public offering (IPO) to support three experimental RNA medicines, with clinical milestones approaching across programs targeting blood clots, eye disease and anemia. 12 October 2026
Biotechnology
Iambic Therapeutics, the San Diego-based AI drug discovery company, has set terms for a Nasdaq initial public offering of 9,375,000 shares priced at $15 to $17 each, under the proposed ticker IAM, according to an amended S-1 filed with the SEC Thursday. 9 October 2026
Biotechnology
Belgian life sciences company SpectaCell has launched with 6 million euros ($6.7 million) in seed financing to develop a cell analysis platform intended to help drugmakers assess immune therapies, from early research through manufacturing. 9 October 2026
Biotechnology
Biohub, the nonprofit research institute combining AI and biology, has joined the US Department of Energy (DOE), the National Institutes of Health (NIH) and technology partners in an expansion of its Virtual Biology Initiative, with $1.8 billion committed in funding, data, computation and measurement technology. 8 October 2026
Biotechnology
US healthcare investment firm TCGX has closed its first Asia-focused life sciences fund at $600 million and is opening offices in Shanghai and Hong Kong to support investments in biotechnology companies across the region. 8 October 2026
Biotechnology
US commercial-stage commercial-stage biotech Rocket Pharmaceuticals announced that it has entered into a credit facility agreement with Hercules Capital for up to $150 million. 7 October 2026
Biotechnology
Dutch life sciences venture capital firm Forbion has raised 2.3 billion euros ($2.6 billion) across two new funds, its largest fundraising to date. The firm said the raise substantially exceeded its target and was completed at pace, and describes it as one of the largest life sciences venture fundraisings globally in the past five years. 7 October 2026
Pharmaceutical
Some three-quarters of senior biopharma executives expect appetite for partnering and M&A to rise over the next 12 months, and none expect it to fall, according to the inaugural Biopharma C-Suite Agenda Survey from BIO-Europe, the partnering event run by Informa Connect. 7 October 2026
Biotechnology
US biotech company Caribou Biosciences plans to stop developing its two clinical cell therapy candidates and substantially reduce its workforce while exploring a possible merger or sale. Shares fell about 35% in after-hours trading on Tuesday following the announcement. 7 October 2026
Biotechnology
UK-based Sensible Biotechnologies, a firm developing naturally modified mRNA made in living cells, has secured $47 million in financing, comprising a Series A led by Oxford Science Enterprises and up to $20 million in non-dilutive funding from the government of Slovakia and the European Union. 6 October 2026
Biotechnology
TRex Bio, the US clinical-stage immunology company built on regulatory T cell (Treg) biology, has set terms for a Nasdaq initial public offering of 8,333,334 shares priced at $14 to $16 each, under the proposed ticker TRXB. 6 October 2026
Biotechnology
Dutch preclinical biotech RougeTx has launched with a $58 million Series A financing to advance RTX-001, a potential once-daily oral treatment for hereditary hemorrhagic telangiectasia (HHT), a serious inherited bleeding disorder with no approved therapies. 6 October 2026
Pharmaceutical
US space manufacturing company Varda Space Industries has raised $251 million in Series D financing to expand its orbital pharmaceutical operations, bringing its total funding to $598 million as it works toward producing medicines in space for use on Earth. 1 October 2026
Pharmaceutical
NorthStar Medical Technologies, the US radiopharma company, has secured a multi-year growth capital facility of up to $185 million from Hercules Capital, the specialty finance company, to expand its isotope production and radiopharmaceutical manufacturing capacity. 1 October 2026
Biotechnology
USA-based Pyxis Oncology announced the pricing of its registered public offering, which is expected to yield approximately $110 million in gross proceeds before expenses. The company’s stock fell 25% to $2.17 on the news. 30 September 2026
Pharmaceutical
US biotech Scynexis has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services, to advance development of SCY-247, its second-generation fungerp antifungal candidate. 30 September 2026
Pharmaceutical
IDA Ireland has released a new whitepaper setting out how the country intends to strengthen its role as a global center for biopharmaceutical manufacturing. The report highlights stability, regulatory strength and a deep talent base as crucial advantages as companies navigate geopolitical shifts and rapid advances in technology. 4 December 2025
Pharmaceutical
Actithera has appointed radiopharmaceutical specialist Darshan Dalal as chief medical officer as the Norwegian and American biotech prepares its first fibroblast activation protein radioligand to enter human studies. Dr Dalal will lead clinical strategy and shape the company’s development group as its precision-engineered pipeline expands. 3 December 2025
Pharmaceutical
Swiss biotech Vandria has unveiled encouraging first-in-human data for VNA-318, an oral small molecule designed to restore mitochondrial function and cut inflammation in Alzheimer’s disease. The readout, presented at the CTAD meeting in San Diego, supports plans for a Phase II proof-of-concept trial. 3 December 2025
Biotechnology
Axoltis Pharma, a French biotech company dedicated to developing novel therapeutic solutions for neurodegenerative diseases, today announced the closing of an 18 million euros ($20.9 million) Series A funding round. 2 December 2025
Biotechnology
The European Investment Bank (EIB) and Angelini Ventures—the Italian drugmaker’s corporate venture capital fund—have signed an agreement to provide a total of 150 million euros ($174 million) in financing for European biotechnology, medtech and digital health startups. 2 December 2025
Biotechnology
San Diego-based Protego Biopharma, a biotech developing small molecule therapeutics that reprogram protein folding to address systemic amyloid diseases and other protein misfolding disorders, has completed an oversubscribed $130 million Series B financing. 1 December 2025
Biotechnology
Canadian biotech Morphocell Technologies has completed its series A at $50 million after a $10 million extension led by Investissement Québec and Italy’s CDP Venture Capital. The raise adds to $40 million secured in 2024 and provides more than three years of operating runway. 1 December 2025
Biotechnology
Swiss incubator Xlife Sciences has provided an update on the ongoing listing process of its portfolio company VERAXA Biotech, in which Xlife holds around 19%. 28 November 2025
Pharmaceutical
Chinese vaccine developer Olymvax has filed an application to list H shares on the main board of the Hong Kong Stock Exchange, marking a shift from a single A-share structure to an A+H model as it seeks broader capital access for its expanding vaccine portfolio. 28 November 2025
Biotechnology
Zetagen Therapeutics, a privately-held clinical-stage biotech pioneering first-of-its-kind, intratumoral treatments for metastatic and primary breast cancer, today announced the successful closure of its oversubscribed Series B1 financing round of $12.9 million. 25 November 2025
Biotechnology
Samsung Life Science Fund has announced an equity investment in Phrontline Biopharma, a Chinese biotech advancing a new generation of antibody-drug conjugates (ADCs). 25 November 2025
Biotechnology
San Diego-based Aspen Neuroscience, a biotech developing autologous regenerative therapies, has announced the closing of a $115 million Series C financing round. 25 November 2025
Biotechnology
South Korean clinical-stage biotech ABL Bio has entered license, research and collaboration agreement with US pharma major Eli Lilly for the development of therapeutics by utilizing ABL Bio’s Grabody Platform. 18 November 2025
Pharmaceutical
Solve Therapeutics has secured $120 million in new financing to move its solid-tumor antibody–drug conjugate (ADC) programs through early clinical development and expand work on its hydrophilic CloakLink linker system. The round, led by Yosemite with a mix of new and existing investors, comes after a $75 million raise in December 2024. 17 November 2025
Pharmaceutical
Artios has closed an oversubscribed $115 million series D to accelerate development of its DNA damage response pipeline, widening studies for lead candidate alnodesertib and advancing a second potential first-in-class program. 17 November 2025
Pharmaceutical
Sofinnova Partners, a European life sciences venture capital firm based in Paris, London and Milan, today announced the close of its latest flagship fund, Sofinnova Capital XI, at 650 million euros ($750 million), greatly exceeding its initial target. 17 November 2025
Biotechnology
Chinese biotech Biokin Pharmaceutical has postponed its planned Hong Kong share listing, citing prevailing market conditions as analysts point to cooling risk appetite late in the year. 14 November 2025
Biotechnology
UK-based life sciences venture capital firm Medicxi today announced the closing of Medicxi V, a 500 million-euros ($579.5 million) fund dedicated to building and backing innovative European biotechnology companies with clear product visions to transform patient care. 14 November 2025
Pharmaceutical
Gate Bioscience has raised $65 million in an oversubscribed series B to advance its first molecular gate candidates, a novel class of oral small molecules designed to eliminate disease-driving proteins before they are secreted. The round was led by Netherlands-based Forbion, with new backing from US pharma major Eli Lilly (NYSE: LLY). 14 November 2025
Pharmaceutical
Swiss clinical-stage biotech, which is pioneering fully synthetic vaccines, today announced the completion of a $15 million financing round from existing shareholders. 13 November 2025
Company Spotlight
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze